Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency
Portfolio Pulse from Vandana Singh
Bavarian Nordic has submitted clinical data to the European Medicines Agency to extend the use of its Imvanex vaccine to adolescents aged 12-17. The vaccine, known as Jynneos in the U.S., is currently approved for adults. The submission is based on a study showing similar immune responses and safety profiles in both adolescents and adults. Bavarian Nordic is also planning a trial for children aged 2-12. The company has a stock of ready-to-ship doses and expects to deliver 2 million doses by the end of the year. Bavarian Nordic's stock rose 15.39% to $14.02.
August 16, 2024 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bavarian Nordic has submitted clinical data to the EMA to extend the use of its Imvanex vaccine to adolescents aged 12-17. The stock rose 15.39% to $14.02.
The submission to the EMA could significantly expand the market for Bavarian Nordic's Imvanex vaccine, potentially increasing future revenues. The stock price has already reacted positively, rising 15.39%.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Bavarian Nordic has submitted clinical data to the EMA to extend the use of its Imvanex vaccine to adolescents aged 12-17. The stock rose 15.39% to $14.02.
The submission to the EMA could significantly expand the market for Bavarian Nordic's Imvanex vaccine, potentially increasing future revenues. The stock price has already reacted positively, rising 15.39%.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100